When combined, a subjective list of common childhood behaviors (fidgeting, losing things, distractibility, not following ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

The FDA now requires ADHD extended-release drug labels to warn of weight loss risks in children under 6, urging monitoring ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

New Zealanders with attention-deficit hyperactivity disorder (ADHD) will now have easier access to diagnosis and medication after the government changed prescribing rules. But there is still so much ...

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side ...

Researchers reviewing nearly 300 top-tier ADHD drug trials found that half skipped the rigorous, expert-led evaluations ...

This summary encapsulates recent health updates including Carmat's insolvency filing, Bayer's glyphosate litigation in the U.S. Supreme Court, FDA's label revisions for ADHD stimulants, a U.S. House ...

Telehealth prescribing of stimulants for teens and adults with ADHD is not linked to a higher risk for substance use disorder vs in-person prescribing, a new study shows.

Collegium's new ADHD drugs may allow the company to grow revenues faster and pay off debt faster. Click here to find out why ...